IL6 and neoplasm: Indeed, high serum levels of CXCL8 and IL-6 in melanoma have been associated with melanoma progression (22), higher tumor burden (54–57), and shorten PFS and OS in patients treated with biochemotherapy (54–56), Ipilimumab (57–59) and Nivolumab (58, 59).